Bertrand Jordan, Daniel Chan, Herb Heyneker, and Peter Lockey have all been appointed to the scientific advisory board of PamGene.
The Den Bosch, Netherlands, microarray company said its board now includes eight members in areas such as oncology, infectious diseases, bioinformatics, genetics, pharmaceutical research and development, immunology, and proteomics.
Jordan is a molecular biologist whose work focuses on large-scale transcript analyis and genomics research, and has been a director of research at France’s Centre Nationale de Recherches Scientifiques, or CNRS.
Chan is a professor of pathol-ogy, oncology, urology and radiol-ogy at the John Hopkins University Medical School, director of clinical chemistry, Johns Hopkins Hospital, and director of the biomarker discovery center at Hopkins’ Sidney Kimmel Comprehensive Cancer Center. His research focuses on cancer proteomics, according to the Cancer Center website.
Heyneker is a veteran in biotechnology R&D. After having served as the founding chief scientific officer of Genentech from 1976 to 1984, he joined the spinoff Genencor as vice president of R&D. He also founded Eos, a biotechnology company, and served as chief technology officer until the company was acquired by Protein Design Labs earlier this year. He now works as an advisor to Abingworth, a Palo Alto- and London- based venture capital firm.
Lockey is director of biochemistry and high-throughput screening at Argenta Discovery of Harlow, Essex, UK. Prior to joining Argenta, he led teams in the high-throughput screening and assay development groups at Aventis UK.
Peter Wagner, founder, senior vice president and CTO of Zyomyx, has been named one of the ten 2004 technology pioneers by the World Economic Forum.
Wagner has been selected for leadership and “innovative research” in the protein biochip technology field. This technology pioneers program was established in 2000 to identify and integrate companies involved in designing and developing new technologies, to monitor and highlight the innovations, and to explore “possible societal repercussions,” according to the WEF.
“I am honored to have been selected by the World Economic Forum, and I look forward to contributing to the technology pioneers community as a member of this distinguished group,” stated Wagner. “I am very proud of the accomplishments Zyomyx has made to the fields of proteomics and bionanotechnology, including this year’s launch of the first automated protein profiling biochip system.”
Kenneth Weisshar has been elected to the board of directors of Digene, the Gaithersburg, Md., company said last week.
Weisshar served as chief operating officer and strategy advisor of Sensatex/Life Link from 2000 to 2003. Before joining Sensatex, he held a number of senior positions at Becton, Dickinson & Company, including chief financial officer; president, worldwide consumer health care; sector president, bioscience cell analysis; president BD division; and vice president corporate planning and development. From 1982 to 1988 he was a consultant at McKinsey & Company, and was employed by Raychem Corporation between 1974 and 1982.